The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Phosphoinositide 3-kinase (PI3K) plays a critical role in tumorigenesis, and the PI3K p85 regulatory subunit exerts both positive and negative effects on signaling. Expression of Pik3r1, the gene encoding p85, is decreased in human prostate, lung, ovarian, bladder, and liver cancers, consistent with the possibility that p85 has tumor suppressor properties. We tested this hypothesis by studying mice with a liver-specific deletion of the Pik3r1 gene. These mice exhibited enhanced insulin and growth factor signaling and progressive changes in hepatic pathology, leading to the development of aggressive hepatocellular carcinomas with pulmonary metastases. Liver tumors that arose exhibited markedly elevated levels of phosphatidylinositol (3,4,5)-trisphosphate, along with Akt activation and decreased PTEN expression, at both the mRNA and protein levels. Together, these results substantiate the concept that the p85 subunit of PI3K has a tumor-suppressive role in the liver and possibly other tissues.

[1]  Michiie Sakamoto,et al.  Early HCC: diagnosis and molecular markers , 2008, Journal of Gastroenterology.

[2]  Minshan Chen,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells , 2010, Hepatology.

[3]  Raphael A Nemenoff,et al.  Tumorigenesis and Neoplastic Progression Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model , 2010 .

[4]  Tara L. Kieffer,et al.  Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .

[5]  C. Kahn,et al.  Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. , 2006, Cell metabolism.

[6]  Chien-Jen Chen,et al.  PTEN/MMAC1 mutations in hepatocellular carcinomas , 1999, Oncogene.

[7]  Li Li,et al.  Association between Phosphatidylinositol 3-Kinase Regulatory Subunit p85α Met326Ile Genetic Polymorphism and Colon Cancer Risk , 2008, Clinical Cancer Research.

[8]  J. Wands,et al.  The increasing incidence of hepatocellular carcinoma. , 1999, The New England journal of medicine.

[9]  T. Fujii,et al.  Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. , 2008, JAMA.

[10]  Kohjiro Ueki,et al.  Molecular Balance between the Regulatory and Catalytic Subunits of Phosphoinositide 3-Kinase Regulates Cell Signaling and Survival , 2002, Molecular and Cellular Biology.

[11]  James G. Fox,et al.  The Mouse in biomedical research , 2007 .

[12]  P. Schirmacher,et al.  Dysregulation of growth factor signaling in human hepatocellular carcinoma , 2006, Oncogene.

[13]  Yuval Inbar,et al.  Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.

[14]  S. Hirohashi,et al.  Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. , 2005, Journal of hepatology.

[15]  Ji Luo,et al.  The p85α Regulatory Subunit of Phosphoinositide 3-Kinase Potentiates c-Jun N-Terminal Kinase-Mediated Insulin Resistance , 2007 .

[16]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[17]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Varticovski,et al.  The Role of Phosphoinositide 3-Kinase in Taurocholate-induced Trafficking of ATP-dependent Canalicular Transporters in Rat Liver* , 1998, The Journal of Biological Chemistry.

[19]  N. Iizuka,et al.  Gene expression profile linked to p53 status in hepatitis C virus‐related hepatocellular carcinoma , 2003, FEBS letters.

[20]  C. Taniguchi,et al.  Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. , 2005, The Journal of clinical investigation.

[21]  Philip J. Lee,et al.  Glycogen storage disease type I: pathophysiology of liver adenomas , 2007, European Journal of Pediatrics.

[22]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[23]  C. Kahn,et al.  Increased P85α Is a Potent Negative Regulator of Skeletal Muscle Insulin Signaling and Induces in Vivo Insulin Resistance Associated with Growth Hormone Excess* , 2005, Journal of Biological Chemistry.

[24]  C. Kahn,et al.  Critical nodes in signalling pathways: insights into insulin action , 2006, Nature Reviews Molecular Cell Biology.

[25]  J. Backer,et al.  Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit , 1998, Molecular and Cellular Biology.

[26]  P. Robinson.  Hepatocellular carcinoma: development and early detection , 2008, Cancer imaging : the official publication of the International Cancer Imaging Society.

[27]  L. Cantley,et al.  The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. , 2005, Cell cycle.

[28]  H. Huber,et al.  A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes , 2006, Oncogene.

[29]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[30]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[31]  L. Cantley,et al.  Then Negative Regulation of Phosphoinositide 3-Kinase Signaling by p85 and Its Implication in Cancer , 2005 .

[32]  B. Park,et al.  Knockin of mutant PIK3CA activates multiple oncogenic pathways , 2009, Proceedings of the National Academy of Sciences.

[33]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Paradiso,et al.  Molecular pathways and related target therapies in liver carcinoma. , 2007, Current pharmaceutical design.

[35]  Kohjiro Ueki,et al.  Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Kohjiro Ueki,et al.  Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. , 2002, The Journal of clinical investigation.

[37]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[39]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[40]  P. Jeggo,et al.  The life and death of DNA-PK , 2005, Oncogene.

[41]  S. Antonarakis,et al.  Binding of PTEN to Specific PDZ Domains Contributes to PTEN Protein Stability and Phosphorylation by Microtubule-associated Serine/Threonine Kinases* , 2005, Journal of Biological Chemistry.

[42]  Yong Zhang,et al.  Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[43]  M. Loda,et al.  Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Francisca Vazquez,et al.  Phosphorylation of the PTEN Tail Regulates Protein Stability and Function , 2000, Molecular and Cellular Biology.

[46]  I. Batty,et al.  Understanding PTEN regulation: PIP2, polarity and protein stability , 2008, Oncogene.

[47]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[48]  C. Kahn,et al.  Phosphoinositide 3-kinase regulatory subunit p85α suppresses insulin action via positive regulation of PTEN , 2006, Proceedings of the National Academy of Sciences.

[49]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[50]  J. Downward,et al.  Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3‐kinase , 1998, The EMBO journal.

[51]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.